Galderma Group AG Stock

Equities

GALD

CH1335392721

Personal Products

Real-time Estimate Cboe Europe 09:33:30 2024-06-19 EDT 5-day change 1st Jan Change
75.79 CHF +0.95% Intraday chart for Galderma Group AG +1.90% 0.00%

Financials

Sales 2024 * 4.44B 3.92B 6.08B Sales 2025 * 4.97B 4.4B 6.82B Capitalization 20.18B 17.83B 27.66B
Net income 2024 * 209M 185M 287M Net income 2025 * 470M 415M 644M EV / Sales 2024 * 5.08 x
Net Debt 2024 * 2.35B 2.08B 3.22B Net Debt 2025 * 1.81B 1.6B 2.48B EV / Sales 2025 * 4.42 x
P/E ratio 2024 *
102 x
P/E ratio 2025 *
40.7 x
Employees 6,545
Yield 2024 *
0.04%
Yield 2025 *
0.33%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.94%
1 week+1.90%
Current month+2.73%
1 month+0.84%
More quotes
1 week
72.70
Extreme 72.7
77.00
1 month
71.83
Extreme 71.83
77.00
Current year
60.00
Extreme 60
77.00
1 year
60.00
Extreme 60
77.00
3 years
60.00
Extreme 60
77.00
5 years
60.00
Extreme 60
77.00
10 years
60.00
Extreme 60
77.00
More quotes
Date Price Change Volume
24-06-19 75.27 +0.25% 49 324
24-06-18 75.08 +2.50% 221,707
24-06-17 73.25 -2.32% 241,224
24-06-14 74.99 -0.13% 173,500
24-06-13 75.09 +1.65% 212,158

Delayed Quote Swiss Exchange, June 19, 2024 at 09:17 am

More quotes
Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
84.81 USD
Average target price
85.85 USD
Spread / Average Target
+1.23%
Consensus

Annual profits - Rate of surprise